I don't know about you all, but I'd gladly accept a few months of delay in the short-term if it means Breakthrough Status is more likely from Phase 2a/2b results.
Also, Frequency did mention releasing some "top-line" data from the study. This may be delayed as well; but considering how active the company is in communicating, they may still make an update on the Phase 2a, even if it is ongoing.
Finally, let's not forget that they started dosing participants in the P2a in October of 2019. So by now, some patients have likely completed the trial. So, Frequency has some data.